Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00708916 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients
A Phase 1 study of Discoid Lupus Erythematosus, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT00708916: Completed Phase 1 study of Discoid Lupus Erythematosus, sponsored by NYU Langone Health.
NCT00708916 is a Phase 1 study of Discoid Lupus Erythematosus that has completed, run by NYU Langone Health. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00708916, a Phase 1 study of Discoid Lupus Erythematosus, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the clinical and immunological effects of the phosphodiesterase type 4 inhibitor, CC-10004, on skin inflammation associated with cutaneous lupus erythematosus.
Primary Outcome
To evaluate the clinical response of cutaneous lupus patients to CC-10004. From J Invest Dermatol. 2005 Nov; 125(5): 889-894.doi: 10.1111/j.0022-202X.2005.23889.x: The CLASI consists of two scores. One summarizes the activity of the disease on a scale from 0 to 30, higher score translates to more severe disease. The second is a measure of the damage done by the disease on a scale form 0 to 30, higher score translates to more severe disease. Activity is scored on the basis of erythema, scale/hyp
Conditions Studied
Interventions
- DRUG CC-10004
Study Locations (1)
New York
- New York University Tisch Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2008-06 |
| Est. Completion | 2010-08 |
| Phase | Phase 1 |
What the finished NCT00708916 record still lists
NCT00708916 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Discoid Lupus Erythematosus appearing as the primary indexed condition, and to 1 intervention - of which CC-10004 is the first listed.
NCT00708916 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00708916 about?
NCT00708916 is a clinical study titled "Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients". The purpose of this study is to determine the clinical and immunological effects of the phosphodiesterase type 4 inhibitor, CC-10004, on skin inflammation associated with cutaneous lupus erythematosus.
What is the current status of trial NCT00708916?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2008-06. Estimated completion is 2010-08.
What conditions does trial NCT00708916 study?
This clinical trial studies the following conditions: Discoid Lupus Erythematosus.
What interventions are being tested in trial NCT00708916?
The interventions under investigation include: CC-10004 (DRUG).
Who is sponsoring clinical trial NCT00708916?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00708916 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00708916's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia